CareDx, Inc.
CDNA- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001217234
In the last 90 days, CareDx, Inc. insiders filed 0 open-market purchases and 2 sales; 229 institutions reported holding it in 13F filings for Q2 2026, worth $1.50B in total; ARK Invest is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 30, 2026, 1:17 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $21.4M (5.6% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 9, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Revenue | $379.8M | $333.8M | $280.3M | $321.8M | $296.4M |
| Operating expenses | $410.6M | $293.0M | $483.7M | $399.0M | $326.1M |
| Research and development | $71.4M | $72.4M | $81.9M | $90.4M | $76.5M |
| Selling, general and administrative | $107.6M | $123.8M | $117.9M | $100.4M | $75.0M |
| Operating income | -$30.8M | $40.8M | -$203.4M | -$77.2M | -$29.7M |
| Income tax | $271.0K | $310.0K | $141.0K | $379.0K | -$1.43M |
| Net income | -$21.4M | $52.5M | -$190.3M | -$76.6M | -$30.7M |
| EPS, basic | $-0.40 | $1.00 | $-3.54 | $-1.44 | $-0.59 |
| EPS, diluted | $-0.40 | $0.93 | $-3.54 | $-1.44 | $-0.59 |
| Weighted shares, basic | 53.3M | 52.8M | 53.8M | 53.3M | 52.2M |
| Weighted shares, diluted | 53.3M | 56.6M | 53.8M | 53.3M | 52.2M |
| Margins and growth | |||||
| Operating margin | -8.1% | 12.2% | -72.5% | -24.0% | -10.0% |
| Net margin | -5.6% | 15.7% | -67.9% | -23.8% | -10.3% |
| Revenue growth, year over year | +13.8% | +19.1% | −12.9% | +8.6% | +54.2% |
| Net income growth, year over year | −140.6% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 9, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Cash and equivalents | $65.4M | $114.7M | $82.2M | $89.9M | $348.5M |
| Short-term investments | $111.8M | $146.0M | $153.2M | $203.2M | $0 |
| Accounts receivable | $42.6M | $64.6M | $51.1M | $66.3M | $59.8M |
| Inventory | $26.7M | $19.5M | $19.5M | $19.2M | $17.2M |
| Total current assets | $257.1M | $351.8M | $313.7M | $387.8M | $433.4M |
| Property, plant and equipment | $33.0M | $33.6M | $35.2M | $35.5M | $22.0M |
| Goodwill | $40.3M | $40.3M | $40.3M | $37.5M | $37.0M |
| Intangible assets | $32.0M | $38.2M | $45.7M | $43.1M | $50.2M |
| Total assets | $413.2M | $491.1M | $466.8M | $543.0M | $566.6M |
| Accounts payable | $9.99M | $7.69M | $12.9M | $9.94M | $13.3M |
| Total current liabilities | $89.8M | $89.4M | $78.1M | $76.0M | $77.3M |
| Total liabilities | $110.1M | $112.6M | $205.5M | $112.1M | $100.7M |
| Shareholders' equity | $303.1M | $378.4M | $261.3M | $430.9M | $465.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 9, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating cash flow | $42.0M | $38.0M | -$18.4M | -$25.2M | -$19.3M |
| Depreciation and amortization | $15.0M | $14.2M | $14.4M | $11.6M | $8.80M |
| Stock-based compensation | $34.9M | $66.4M | $49.1M | $46.6M | $36.1M |
| Share buybacks | $87.8M | $522.0K | $27.5M | $642.0K | – |
| Investing cash flow | $2.16M | -$483.0K | $40.4M | -$228.5M | $47.7M |
| Financing cash flow | -$93.4M | -$5.61M | -$29.6M | -$4.54M | $185.6M |
| Net change in cash | -$49.3M | $32.5M | -$7.66M | -$258.3M | $213.8M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 9.2% | 19.9% | 17.5% | 14.5% | 12.2% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.